DarDoc Research

GLP-1 Trial & Approval Tracker

All studies

SURMOUNT-2 trial results

Adults with overweight or obesity and type 2 diabetes.

Mounjaro
Phase
Phase 3
Follow-up
72 weeks
Randomised
938
Sponsor
Eli Lilly
Publication
The Lancet · 2023

Double-blind, placebo-controlled. Treatment-regimen analysis.

Mean body weight change at 72 weeks
  • Tirzepatide 10 mg−12.8%
  • Tirzepatide 15 mg−14.7%
  • Placebo−3.2%
Mean body weight change at 72 weeks
Trial armResult
Tirzepatide 10 mg−12.8%
Tirzepatide 15 mg−14.7%
Placebo−3.2%

Safety. Gastrointestinal events such as nausea, diarrhoea and vomiting were the most common adverse events.

Published paper PubMed abstract NCT04657003